Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its competitive position and financial guidance, leading to investor losses during the specified Class Period from May 7, 2025, to August 5, 2025 [3][7]. Allegation Details - The lawsuit claims that LifeMD's defendants overstated the company's competitive position [3]. - It is alleged that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. - As a result, the statements made about LifeMD's business operations and prospects were materially false and misleading [3]. Next Steps - Investors who purchased LifeMD shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 27, 2025 [7].

, /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in LifeMD, Inc. ("LifeMD, Inc." or the "Company") (NASDAQ: LFMD) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of LifeMD, Inc. investors who were adversely affected by alleged securities fraud between May 7, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lifemd-inc-lawsuit-submission-form?prid=171452&wire= ...

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and providing unrealistic financial guidance for 2025, leading to significant investor losses when the truth was revealed [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025 [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representatives [2]. - The complaint alleges that LifeMD did not disclose rising customer acquisition costs related to its RexMD platform and its promotion of obesity medications like Wegovy and Zepbound [3]. Group 2: Company Background - LifeMD, headquartered in New York, provides virtual medical services and prescription delivery [2]. - Berger Montague, the law firm representing the plaintiffs, has a long history in securities class action litigation, having served investors for over five decades [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [1][3]. Group 1: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives made false and misleading statements regarding the company's competitive position and financial guidance [3]. - Specifically, it is claimed that LifeMD's 2025 guidance was raised recklessly without properly accounting for increased customer acquisition costs, particularly in the RexMD segment and for obesity treatment drugs [3]. - As a result of these alleged misstatements, the company's business operations and prospects were deemed materially false and misleading [3]. Group 2: Financial Impact - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from a previous estimate of $268 to $275 million [4]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [4]. Group 3: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against LifeMD is October 27, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5].

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in LifeMD, Inc. ("LifeMD, Inc." or the "Company") (NASDAQ: LFMD) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of LifeMD, Inc. investors who were adversely affected by alleged securities fraud between May 7, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lifemd-inc-lawsuit-submiss ...

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important October 27, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased LifeMD securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive position and financial guidance during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint claims that during the class period from May 7, 2025, to August 5, 2025, LifeMD's defendants overstated the company's competitive position [1]. - It is alleged that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for increasing customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [1]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares of LFMD during the specified timeframe are encouraged to register for the class action by October 25, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In LifeMD To Contact Him Directly To Discuss Their Options If you suffered losses in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading ...

LOS ANGELES, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming October 27, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) securities between May 7, 2025 and August 5, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR LIFEMD INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOU ...

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in LifeMD, Inc. ("LifeMD, Inc." or the "Company") (NASDAQ: LFMD) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of LifeMD, Inc. investors who were adversely affected by alleged securities fraud between May 7, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lifemd-inc-lawsuit-submiss ...